&lt;p&gt;Dry eye disease ranking among common reasons for seeking eye care in a large US claims database&lt;/p&gt;

Bradley, John L.; Stillman, Ipek Özer; Pivneva, Irina; Guérin, Annie; Evans, Amber; Dana, Reza

doi:10.2147/opth.s188314

Cited by 47 publications

(45 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dry eye disease (DED) is a commonly occurring ocular condition and a frequent reason for patients to seek medical eye care. 1 2 Global DED prevalence is estimated to range from 5% to 50%, 2 with estimates in Europe ranging from 10% to 30%. 3–5 In a female cohort in the UK (n=3824; mean age, 57.1 years), the overall prevalence of DED was 9.6% (defined as diagnosis by a clinician and use of artificial tears) and the prevalence of reported symptoms of DED in the previous 3 months was 20.8%.…”

Section: Introductionmentioning

confidence: 99%

Patient-reported burden of dry eye disease in the UK: a cross-sectional web-based survey

et al. 2021

Self Cite

View full text Add to dashboard Cite

ObjectivesTo compare sociodemographics and vision-related quality of life (QoL) of individuals with or without dry eye disease (DED); and to explore the impact of DED symptom severity on visual function, activity limitations and work productivity.DesignCross-sectional web-based survey.SettingGeneral UK population.ParticipantsAdults ≥18 years with (N=1002) or without (N=1003) self-reported DED recruited through email and screened.Main outcome measuresAll participants completed the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25), with six additional questions (items A3–A8), and the EuroQol 5 dimensions 5 levels. DED participants also completed Impact of Dry Eye on Everyday Life questionnaire, 5-item Dry Eye Questionnaire and the Standardised Patient Evaluation of Eye Dryness questionnaire along with the Ocular Comfort Index, Work Productivity and Activity Impairment and the Eye Dryness Score (EDS), a Visual Analogue Scale.ResultsBaseline demographic and clinical characteristics were similar in participants with versus without DED (mean age, 55.2 vs 55.0 years; 61.8% vs 61.0% women, respectively) based on recruitment targets. Scores were derived from NEI VFQ-25 using the new 28-item revised VFQ (VFQ-28R) scoring. Mean (SD) VFQ-28R scores were lower in participants with versus without DED, indicating worse functioning (activity limitations, 73.3 (12.3) vs 84.4 (12.3); socioemotional functioning, 75.3 (21.5) vs 90.3 (16.2); total score, 71.6 (12.8) vs 83.6 (12.6)). Higher percentages of problems/inability to do activities were observed among those with versus without DED. The impact of DED on visual function was worse for participants with more severe DED symptoms, as assessed by EDS. In addition, a higher EDS was associated with worse symptoms on common DED scales and a worse impact on work productivity.ConclusionsDED symptoms were associated with negative effects on visual function, activities and work productivity, whereas worse DED symptoms had a greater impact on vision-related QoL and work productivity.

show abstract

Section: Introductionmentioning

confidence: 99%

Patient-reported burden of dry eye disease in the UK: a cross-sectional web-based survey

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Indeed, dry eye is one of the most common reasons for patients to visit an eye care specialist seeking treatment. 15 Chronic inflammation of the ocular surface can be a consequence as well as a cause of DED. Topical medications such as CYC and LIF can help to break or slow the selfperpetuating inflammatory cycle, but responses are heterogeneous, due in part to the influence of non-modifiable risk factors for DED such as sex-and age-related changes in aqueous tear and lipid production.…”

Section: Discussionmentioning

confidence: 99%

<p>Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease</p>

White¹,

Zhao²,

Jayapalan³

et al. 2020

OPTH

View full text Add to dashboard Cite

Purpose: Dry eye disease (DED) is one of the most common ophthalmic disorders. Pathogenesis of the disease includes inflammation of the ocular surface and lacrimal gland. Two anti-inflammatory prescription treatments are currently available: cyclosporine ophthalmic emulsion 0.05% (CYC) and lifitegrast 5% ophthalmic solution (LIF). The objective of this survey-based study was to assess physician satisfaction with CYC and LIF for the treatment of DED. Methods: Physicians currently treating DED patients with CYC or LIF were asked to rate the experiences of their patients currently or formerly using CYC and LIF, and their own perspectives on the two treatments. Results: Twenty-one physicians participated in the survey, providing responses on behalf of 210 patients. Overall, physicians reported low levels of satisfaction with onset of action of CYC and LIF, and fewer than half considered either drug to be effective in managing symptoms or improving patient quality of life (QoL). Burning sensation and dysgeusia were the most frequently reported side effects. Onset of action and effectiveness after onset were the main switching drivers. Although two-thirds of physicians were satisfied with the overall effectiveness of CYC and LIF, all physicians agreed that more DED treatment options are needed, with >50% strongly agreeing. Conclusion: Physicians perceived a gap in DED management with currently available topical anti-inflammatory agents. Although satisfaction with CYC and LIF was high, few physicians considered these medications to be effective in managing symptoms or improving QoL.

show abstract

“…33 The above findings are clinically relevant, especially when considering that dry eye disease was the only ocular disease associated with an increased incidence between 2008 and 2012. 34…”

Section: Dovepressmentioning

confidence: 99%

<p>Changes in Tear Lipid Layer Thickness and Symptoms Following the Use of Artificial Tears with and Without Omega-3 Fatty Acids: ARandomized, Double-Masked, Crossover Study</p>

Fogt¹,

Fogt²,

King‐Smith³

et al. 2019

OPTH

View full text Add to dashboard Cite

Purpose: To determine if an eye drop containing omega-3 fatty acids (Refresh Optive MEGA-3 ® , Allergan plc, Dublin, Ireland) increases the lipid layer thickness (LLT) of the tear film versus a non-emollient eye drop (Refresh Optive, Allergan plc). Methods: Patients (≥30 years) with baseline LLT ≤75 nm completed the Current Symptoms Survey (CSSa visual analog survey of dry eye symptoms), and LLT was measured pre-and post-instillation (15 and 60 mins) of their randomly assigned treatment. After washout, patients were tested with the other treatment. Primary endpoint: change in LLT from baseline. Secondary endpoint: CSS results. Results: Of 21 patients enrolled, 19 completed the study. With the omega-3-containing eye drop, the mean (standard deviation) LLT increase from baseline at 15 mins was statistically significant in the overall field (8.8 [11.5] nm; P<0.001), and in each individual zone (superior, central, and inferior). At 1 hr, the LLT change from baseline was statistically significant overall (4.4 [9.7] nm; P<0.02) and in the inferior and central zones. With the aqueous eye drop, LLT change from baseline was only significant at 15 mins in the inferior field. The CSS analysis revealed a ≥8.68-unit decrease in mean average dryness score from baseline at 15 and 60 mins post-instillation of the lipid-based treatment (P≤0.03). Conclusion: The eye drop containing omega-3 fatty acids increased LLT at 15 mins, maintaining it at 1 hr post-instillation. Dryness symptoms also improved and maintained improved levels 1 hr after instillation, indicating that the product may benefit symptomatic patients with evaporative dry eye.

show abstract

<p>Dry eye disease ranking among common reasons for seeking eye care in a large US claims database</p>

Cited by 47 publications

References 13 publications

Patient-reported burden of dry eye disease in the UK: a cross-sectional web-based survey

Patient-reported burden of dry eye disease in the UK: a cross-sectional web-based survey

<p>Physician Satisfaction with Anti-Inflammatory Topical Medications for the Treatment of Dry Eye Disease</p>

<p>Changes in Tear Lipid Layer Thickness and Symptoms Following the Use of Artificial Tears with and Without Omega-3 Fatty Acids: ARandomized, Double-Masked, Crossover Study</p>

Contact Info

Product

Resources

About